Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat shock protein nuclear import factor Hikeshi (HIKESHI) is a nuclear transport receptor that mediates the nuclear import of heat-shock proteins—particularly the molecular chaperone Hsp70—under heat shock and cellular stress conditions[1][2][3]. Unlike classical importins, Hikeshi is activated when importin-mediated nuclear import is downregulated by stress, ensuring a continued supply of chaperones to the nucleus to counteract heat-induced protein aggregation and damage, thereby promoting cell survival[1]. Hikeshi contains an N-terminal FG-binding domain and a C-terminal dimerization domain, forming an asymmetric dimer that specifically recognizes ATP-bound Hsp70[1]. Under certain conditions, Hikeshi auto-inhibition is relieved to facilitate nuclear import. Genetically, HIKESHI is located on chromosome 11 in humans and loss-of-function mutations have been associated with severe hereditary neurodevelopmental disorders[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein nuclear import factor Hikeshi (HIKESHI).